tbuckley/cabot-search huggingface dataset:
Abstract 16082: HDAC1 Plays an Essential Role in the Differentiation of Embryonic and Induced Pluripotent Stem Cells into Cardiovascular Lineages.
Authors: Eneda Hoxha, Erin Lambers, Melissa Thal, Suresh Verma, Prasanna Krishnamurthy, Raj Kishore
Journal: Circulation (2010)

Despite advancements in the treatment of myocardial infarction (MI), the majority of patients are at increased risk for developing heart failure due to the loss of cardiomyocytes and microvasculature. Therefore regenerative medicine is considered one of the most promising therapies in this field. However, reasons that continue to hinder in the realization of the full potential of iPS/ES cells include incomplete understanding of the molecular mechanisms and epigenetic modifications that result in the reprogramming of somatic cells and directed cardiovascular differentiation. Real-Time array experiments revealed that HDAC1 is highly expressed in pluripotent cells. Additionally the lack of this molecule is embryonically lethal, suggesting it plays a key role in development. Thus, we hypothesized that HDAC1 plays a critical role in maintaining pluripotency and directing cardiovascular differentiation of mES and iPS cells in vitro. HDAC1 was stably knocked down in mES cells (C57BL/6) and iPS cells using a shRNA vector. Differentiation was induced in wild type mES and iPS cell as well as in their clones in which HDAC1 was selectively knocked down. We monitored the ability of these cells to differentiate into any of the three early embryonic lineages and more specifically cardiovascular lineage. RNA was isolated from embryoid bodies on day 4, 6, 8 and 10. Embryoid bodies lacking HDAC1 differentiated slower and showed delayed suppression of pluripotent genes such as Oct4 and Nanog. In addition cells lacking HDAC1 showed differential expression of early endodermal, mesodermal and ectodermal markers. Beating of the embryoid bodies in HDAC1 knocked down cells was also delayed and fewer embryoid bodies showed spontaneous beating. Expression of cardiomyocyte markers as well as markers of other cardiovascular lineage cells was significantly repressed in HDAC1 knocked down cells. Taken together our data suggests that HDAC1 plays a critical role in directing cardiovascular differentiation of mES and iPS cells. Further research in the molecular mechanisms involved in this process will greatly aid our understanding of the epigenetic circuity of pluripotency and cardiovascular differentiation in ES and iPS cells.
Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney
Authors: Rie Utoh, Junji Komori, Hiroyuki Kuge, Kohei Tatsumi, Masumi Yamada, Shinji Hirohashi, Masahiro Tsutsumi, Toshihiro Amanuma, Akira Yoshioka, Yoshiyuki Nakajima, Kenjiro Wake, Teruo Okano, Eric Lagasse, Kazuo Ohashi
Journal: Journal of Hepatology (2017)
Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases
Authors: Sonia Mahajan, Ashok Shaha, Ravinder K. Grewal
Journal: Clinical Nuclear Medicine (2017)

Ga-DOTATATE, a positron-emitting somatostatin analog, has been approved by the Food and Drug Administration for imaging neuroendocrine tumors (NETs). The presence of a second primary malignancy is common in NETs; however, synchronous primary malignancy in the thyroid has rarely been reported. The value of Ga-DOTATATE in medullary thyroid cancer is being investigated and is currently recommended for use when treatment with somatostatin analogs is an option. We present a 55-year-old man with abdominal pain associated with well-differentiated NET liver metastases and incidental medullary thyroid carcinoma demonstrated on a Ga-DOTATATE PET/CT.
Loss of Fhit expression in head and neck squamous cell carcinoma and its utility in individualized therapy.
Authors: Shyh-Kuan Tai, Janet I. Lee, K. Kian Ang, Adel K. El-Naggar, Khaled A. Hassan, Diane Liu, Waun K. Hong, Li Mao
Journal: Cancer Research (2004)

3702   Radiotherapy (RT) is an important treatment modality for head and neck squamous cell carcinomas (HNSCC). Locoregional recurrence and distant metastasis remain common problems for advanced cases despite the aggressive combination treatment strategies with increased toxicity. Molecular markers that better predict survival and the likelihood of responding to RT are helpful in the decision of treatment planning and prognostic classification. We have previously shown that loss of Fhit predicts a poor clinical outcome in patients with oral tongue cancer treated by surgery. To define the role of Fhit in HNSCC treated with surgery and RT, we analyzed Fhit expression in tissue sections from 80 patients, who enrolled in a prospective Phase III clinical trial addressing the dose and fractionation regimen of postoperative RT. The median follow-up duration was 4.9 years. Positive Fhit expression was generally shown in normal squamous epithelium, and heterogenous Fhit expression was commonly found in tumors. Loss of Fhit expression was found in 52 of the 80 (65%) patients. There was no significant correlation between Fhit expression and age, gender, clinical stage, risk group or tumor grade. However, patients whose tumors demonstrated loss of Fhit expression had a significantly worse 5-year overall survival ( P =0.05). A trend toward more distant metastasis was observed in patients whose tumors showed loss of Fhit expression. Interestingly, the high-risk patients whose tumor showed loss of Fhit expression appeared to have a better local regional control. We hypothesize that loss of Fhit expression facilitates the response to postoperative RT by relieving the cells from cell cycle arrest and apoptosis resulting a better loco-regional control. Tumor cells outside the RT area survived the treatment and contribute to the systemic failure. Thus, Fhit expression status might be a selection biomarker for novel adjuvant chemotherapy trial in advanced cases currently under locoregional control.
In Vitro Expanded γδ T Cells Derived from Cord Blood Induce Potent and Specific Cytotoxicity Against Human Acute Myeloid Leukemia Cells
Authors: Alice MS Cheung, Kar Wai Tan, Dian Yan Guo, Su-Ann Goh, Amanda SY Lau, Yeh Ching Linn, William YK Hwang, Yeow Tee Goh, Shang Li
Journal: Blood (2016)
Association Between Medicare Expenditure Growth and Mortality Rates in Patients With Acute Myocardial Infarction
Authors: Donald S. Likosky, Jessica Van Parys, Weiping Zhou, William B. Borden, Milton C. Weinstein, Jonathan S. Skinner
Journal: JAMA Cardiology (2017)

Many studies have considered the association between Medicare spending and health outcomes at a point in time; few have considered the association between the long-term growth in spending and outcomes.To assess whether components of growth in Medicare expenditures are associated with mortality rates between January 1, 1999, and June 30, 2014, for beneficiaries hospitalized for acute myocardial infarction.Cross-sectional analysis of a random 20% sample of fee-for-service Medicare beneficiaries from January 1, 1999, through December 31, 2000 (n=72 473) and January 1, 2004, through December 31, 2004 (n=38 248), and 100% sample from January 1, 2008, through December 31, 2008 (n=159 558) and January 1, 2013, through June 30, 2014 (n=209 614) admitted with acute myocardial infarction to 1220 hospitals.Primary exposure measures include the growth of 180-day expenditure components (eg, inpatient, physician, and postacute care) and early percutaneous coronary intervention by hospitals adjusted for price differences and inflation. The primary outcome is the risk-adjusted 180-day case fatality rate.Patients in each of the years 2004, 2008, and 2013-2014 (relative to those in 1999-2000) were qualitatively of equivalent age, less likely to be white or female, and more likely to be diabetic (all P < .001). Adjusted expenditures per patient increased 13.9% from January 1, 1999, through December 31, 2000, and January 1, 2013, through June 30, 2014, but declined 0.5% between 2008 and 2013-2014. Mean (SD) expenditures in the 5.0% of hospitals (n = 61) with the most rapid expenditure growth between 1999-2000 and 2013-2014 increased by 44.1% ($12 828 [$2315]); for the 5.0% of hospitals with the slowest expenditure growth (n = 61), mean expenditures decreased by 18.7% (-$7384 [$4141]; 95% CI, $8177-$6496). The growth in early percutaneous coronary intervention exhibited a negative association with 180-day case fatality. Spending on cardiac procedures was positively associated with 180-day mortality, while postacute care spending exhibited moderate cost-effectiveness ($455 000 per life saved after 180 days; 95% CI, $323 000-$833 000). Beyond spending on noncardiac procedures, growth in other components of spending was not associated with health improvements.Health improvements for patients with acute myocardial infarction varied across hospitals and were associated with the diffusion of cost-effective care, such as early percutaneous coronary intervention and, to a lesser extent, postacute care, rather than overall expenditure growth. Interventions designed to promote hospital adoption of cost-effective care could improve patient outcomes and, if accompanied by cuts in cost-ineffective care (inside and outside of the hospital setting), also reduce expenditures.
Recent progress on biodegradable materials and transient electronics
Authors: Rongfeng Li, Liu Wang, Deying Kong, Lan Yin
Journal: Bioactive Materials (2017)

Transient electronics (or biodegradable electronics) is an emerging technology whose key characteristic is an ability to dissolve, resorb, or physically disappear in physiological environments in a controlled manner. Potential applications include eco-friendly sensors, temporary biomedical implants, and data-secure hardware. Biodegradable electronics built with water-soluble, biocompatible active and passive materials can provide multifunctional operations for diagnostic and therapeutic purposes, such as monitoring intracranial pressure, identifying neural networks, assisting wound healing process, etc. This review summarizes the up-to-date materials strategies, manufacturing schemes, and device layouts for biodegradable electronics, and the outlook is discussed at the end. It is expected that the translation of these materials and technologies into clinical settings could potentially provide vital tools that are beneficial for human healthcare.
Frequency of Chronic Joint Pain Following Chikungunya Virus Infection
Authors: Aileen Y. Chang, Liliana Encinales, Alexandra Porras, Nelly Pacheco, St. Patrick Reid, Karen A. O. Martins, Shamila Pacheco, Eyda Bravo, Marianda Navarno, Alejandro Rico Mendoza, Richard Amdur, Priyanka Kamalapathy, Gary S. Firestein, Jeffrey M. Bethony, Gary L. Simon
Journal: Arthritis & Rheumatology (2017)

Objective To estimate the frequency of chronic joint pain after infection with chikungunya virus in a Latin American cohort. Methods A cross‐sectional follow‐up of a prospective cohort of 500 patients from the Atlántico Department, Colombia who were clinically diagnosed as having chikungunya virus during the 2014–2015 epidemic was conducted. Baseline symptoms and follow‐up symptoms at 20 months were evaluated in serologically confirmed cases. Results Among the 500 patients enrolled, 485 had serologically confirmed chikungunya virus and reported joint pain status. Patients were predominantly adults (mean ± SD age 49 ± 16 years) and female, had an education level of high school or less, and were of Mestizo ethnicity. The most commonly affected joints were the small joints, including the wrists, ankles, and fingers. The initial virus symptoms lasted a median of 4 days (interquartile range [ IQR ] 3–8 days). Sixteen percent of the participants reported missing school or work (median 4 days [ IQR 2–7 days]). After 20 months, one‐fourth of the participants had persistent joint pain. A multivariable analysis indicated that significant predictors of persistent joint pain included college graduate status, initial symptoms of headache or knee pain, missed work, normal activities affected, ≥4 days of initial symptoms, and ≥4 weeks of initial joint pain. Conclusion This is the first report to describe the frequency of chikungunya virus–related arthritis in the Americas after a 20‐month follow‐up. The high frequency of chronic disease highlights the need for the development of prevention and treatment methods.
Dietary antioxidants and 10-year lung function decline in adults from the ECRHS survey
Authors: Vanessa Garcia-Larsen, James F. Potts, Ernst Omenaas, Joachim Heinrich, Cecilie Svanes, Judith Garcia-Aymerich, Peter G. Burney, Deborah L. Jarvis
Journal: European Respiratory Journal (2017)

The relationship between lung function decline and dietary antioxidants over 10 years in adults from three European countries was investigated. In 2002, adults from three participating countries of the European Community Respiratory Health Survey (ECRHS) answered a questionnaire and underwent spirometry (forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC)), which were repeated 10 years later. Dietary intake was estimated at baseline with food frequency questionnaires (FFQ). Associations between annual lung function decline (mL) and diet (tertiles) were examined with multivariable analyses. Simes’ procedure was applied to control for multiple testing. A total of 680 individuals (baseline mean age 43.8±6.6 years) were included. A per-tertile increase in apple and banana intake was associated with a 3.59 mL·year −1 (95% CI 0.40, 7.68) and 3.69 mL·year −1 (95% CI 0.25, 7.14) slower decline in FEV 1 and FVC, respectively. Tomato intake was also associated with a slower decline in FVC (4.5 mL·year −1 ; 95% CI 1.28, 8.02). Only the association with tomato intake remained statistically significant after the Simes’ procedure was performed. Subgroup analyses showed that apple, banana and tomato intake were all associated with a slower decline in FVC in ex-smokers. Intake of fruits and tomatoes might delay lung function decline in adults, particularly in ex-smokers.
An update on high-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Authors: Ryan Eldredge Wilcox, Mark Robert Litzow, Evanthia Galanis, Paula Gill, Jan C. Buckner
Journal: Journal of Clinical Oncology (2014)

2043 Background: Recurrent embryonal tumors of the central nervous system (CNS) in adults are rare and have a poor prognosis. High-dose chemotherapy followed by autologous stem cell transplant (HDC/ASCT) in our previous experience has shown to result in durable responses. (Gill; Cancer 2008; Apr 15;112(8):1805-11). We present an updated report of the Mayo Clinic experience. Methods: We performed a retrospective review of adults (age ≥18) with recurrent embryonal tumors at our institution treated with HDC/ASCT between 1998 and 2012. Kaplan-Meier method was used to calculate time to event and survival analysis. Results: 19 patients were identified: 14 medulloblastoma, 4 PNET/cerebral neuroblastoma, and 1 pineoblastoma. Median follow up was 120 mo. (95% CI: 74-157). At initial diagnosis, median age was 28 yrs. (18-64); 58% were male; 63%, 32% and 5% had gross total, subtotal, and no resection; 95 % had radiation therapy, and 53% had chemotherapy. Median time to first relapse was 58 mo. (12 - 146) and median time from relapse to transplant was 5 mo. (3 - 17). At first recurrence, median age was 35 yrs (21 - 65); M-stage was: M0 in 42%, M1 in 0%, M2 in 5%, M3 in 32%, and M4 in 21%, 11 pts had gross total, and 4 had subtotal resection; 2 had radiation, and 15 were treated with induction chemotherapy, with 87% receiving a platinum containing regimen. Prior treatment response status at transplant was CR in 37%, PR in 47%, and PROG in 16%. Most patients had tandem peripheral blood stem cell transplant following conditioning with ThioTEPA/BCNU then ThioTEPA/Carboplatin, (completed in 95% and 79% respectively). From first recurrence, mTTP was 23 mo. (95% CI: 15 - 49), and mOS was 35 mo. (95% CI: 24 - 50). 2-, 5-, and 10- year survival were 68%, 38%, and 14% respectively. There were no treatment related mortalities. Conclusions: These data in 19 adult patients confirm earlier observations in smaller patient cohorts, compare favorably with historic controls treated with standard dose chemotherapy in our institution, and support HDC/ASCT in adults with recurrent embryonal tumors of the CNS as a viable therapeutic option in appropriate patients.
Nonsyndromic Retinitis Pigmentosa in the Ashkenazi Jewish Population
Authors: Adva Kimchi, Samer Khateb, Rong Wen, Ziqiang Guan, Alexey Obolensky, Avigail Beryozkin, Shoshi Kurtzman, Anat Blumenfeld, Eran Pras, Samuel G. Jacobson, Tamar Ben-Yosef, Hadas Newman, Dror Sharon, Eyal Banin
Journal: Ophthalmology (2017)
Tocilizumab increased sustained glucocorticoid-free remission from giant cell arteritis
Authors: Nataliya Milman
Journal: Annals of Internal Medicine (2017)

ACP Journal Club19 December 2017Tocilizumab increased sustained glucocorticoid-free remission from giant cell arteritisNataliya Milman, MDNataliya Milman, MDUniversity of Ottawa, Ottawa, Ontario, Canada (N.M.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-167-12-063 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationStone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317-28. https://pubmed.ncbi.nlm.nih.gov/28745999Clinical Impact RatingsGIM/FP/GP: Rheumatology: Reference1 Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789-97. [PMID: 17665429] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Ottawa, Ottawa, Ontario, Canada (N.M.)This article was published at Annals.org on 5 December 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClearinghouse Standards of Evidence on the Transparency, Openness, and Reproducibility of Intervention EvaluationsInformation RetrievalPlacement delivery array design for the coded caching scheme in medical data sharingInformationChallenges of international oncology trial collaboration—a call to actionOpen science: The open clinical trials data journeyA beginner's guide to data stewardship and data sharingThe U.S. Environmental Protection Agency's Proposed Transparency Rule Threatens HealthRenee N. Salas, MD, MPH, MS, Francine Laden, ScD, Wendy B. Jacobs, JD, and Ashish K. Jha, MD, MPHAmerican College of Physicians Ethics Manual Seventh EditionLois Snyder Sulmasy, JD and Thomas A. Bledsoe, MD, for the ACP Ethics, Professionalism and Human Rights Committee*DASH, the data and specimen hub of the National Institute of Child Health and Human DevelopmentEthical concerns on sharing genomic data including patients' family membersBe open about drug failures to speed up researchA Data Sharing Policy for Anaesthesia and Intensive CareData Sharing Statements for Clinical Trials: One Step Down the RoadDarren B. Taichman, MD, PhD and Christine Laine, MD, MPH 19 December 2017Volume 167, Issue 12Page: JC63KeywordsAminotransferasesC-reactive proteinsChronic obstructive pulmonary diseaseGiant cellsOsteoporosisRenal diseasesRheumatoid arthritisRheumatologySafetyVaccines ePublished: 19 December 2017 Issue Published: 19 December 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Human-Machine Collaboration—A New Form of Paternalism?—Reply
Authors: Ian M. Goldstein, Julie Lawrence, Adam S. Miner
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
NIH PROMIS (Patient Reported Outcomes Measurement Information System) among patients with neoplasms.
Authors: Ekokobe Fonkem, Kerry O'Mahar, Haydee Becerril, Abigail Bernett, Jared Benge, Daniel Cruz, Richard Phenis
Journal: Journal of Clinical Oncology (2014)

e13000 Background: Quality of life (QOL) is increasingly incorporated as a critical endpoint in clinical and research trials in neuro-oncology. If QOL is to be used to guide clinical and research decision-making, it is critical to (1) include this variable in assessment of patient functioning and (2) measure QOL accurately. Such measurement research has heretofore been hampered by the variety of instruments utilized and limited psychometric research in various neuro-oncology populations. Recently, the National Institutes of Health (NIH) has produced Patient-Reported Outcomes Measurement Information System (PROMIS) to assess QOL in various patient populations. This assessment tool went through rigorous development and is well supported from a psychometric perspective. This study will present (1) descriptive information regarding some of the QOL domains PROMIS can assess, (2) the frequencies of concerns in various domains this sample of brain tumor patients reports (3) whether QOL differs by various medical variables. Methods: Patients presenting to a neuro-oncology clinic (n=100) at a Level I hospital completed the PROMIS questionnaire as part of their clinic appointment. Each item is rated on a 5-point likert scale. Results: Patient age ranged from 18-86 years. For treatment, 57% had surgery, 56% had radiation, 42% had chemotherapy, and 12% had TTF (tumor treating field) intervention. Tumors were classified as high (less than two year expected survival time) and low grade, as designated by the neuro-oncologist. This sample consisted of 45% high grade. Preliminary results for the entire sample indicated relatively low rates of anxiety, depression, and sleep difficulties, but lower QOL related to cognitive difficulties. Conclusions: The current study demonstrates the feasibility of the PROMIS measures for capturing QOL in a clinic based neuro-oncology sample. Initial results suggest that patients identified cognitive side effects as a cause of diminished QOL but patients did not frequently report mood symptoms (anxiety/depression).